TABLE 3.

Urine volume output, urinary sodium excretion, PS volume and dietary fluid intake

	Analysis part A		Analysis parts A + B
Secondary end point	5 mg vs placebo (n = 8)	P‐value	10 mg vs placebo (n = 8)	P‐value	5 mg vs 10 mg (n = 8)	P‐value
Absolute urine volume, ml/day	714 (490–939)	.002	795 (195–1394)	.014	84 (−514 to 682)	.761
Relative urine volume, %	49 (4–94)	.041	34 (−4 to 71)	.072	−14 (−51 to 23)	.420
Urine sodium excretion, mmol/day	66 (−69 to 201)	.171	88 (20–156)	.017	32 (−37 to 101)	.325
Urine sodium excretion, %	189 (−350 to 729)	.270	432 (−87 to 951)	.092	266 (−266 to 798)	.287
PS volume, ml/day	−94 (−344 to 156)	.356	−469 (−941 to 4)	.052	−380 (−851 to 91)	.103
Relative PS volume, %	−13 (−41 to 15)	.276	−28 (−51 to −4)	.025	−15 (−38 to 9)	.195
Dietary fluid intake, ml/day	−242 (−560 to 76)	.103	−363 (−641 to −86)	.015	−119 (−396 to 157)	.362
Relative dietary fluid intake, %	−9 (−18 to 1)	.068	−15 (−25 to −5)	.006	−7 (−17 to 3)	.169
Plasma citrulline, μmol/L	17.7 (−6.3 to 41.7)	.100	14.0 (−2.3 to 30.3)	.084	−3.6 (−19.8 to 12.6)	.632
Relative plasma citrulline, %	66 (−13 to 145)	.077	42 (−10 to 94)	.100	−23 (−74 to 29)	.344

Note: Data represent mean (95% CI), adjusted for the period‐specific baseline value of each end point, PS, and dietary fluid intake in a two‐sided analysis of covariance model. Part A was also adjusted for period, whereas parts A + B assumed no period effect.

Abbreviation: PS, parenteral support.